Development · 19 Sep 2026
2 publishers have reported this development. Each act of reporting is below, cited.
Haleos Labs announced that the United States Food and Drug Administration (USFDA) has successfully conducted an inspection of Mahi Drugs at its API manufacturing facility, concluding with zero Form 483 observations.
Haleos Labs announced that the United States Food and Drug Administration (USFDA) has successfully conducted an inspection of Mahi Drugs at its API manufacturing facility from September 15, 2026, to September 18, 2026.
The United States Food and Drug Administration (USFDA) successfully conducted an inspection of Mahi Drugs' API manufacturing facility from September 15, 2026, to September 18, 2026, with zero Form 483 observations.
This page is the corroborated record of one development: what each credible source reported, linked and dated. We compile and cite; we do not opine.
New here? The reader's guide explains every page, plate by plate.
fregime is informational research software. Content on this page is factual reporting compiled from cited public sources; nothing here is advice, and nothing here expresses an opinion on any security. fregime is not registered with SEBI as an investment adviser or research analyst. Before making investment decisions, consult a SEBI-registered adviser. Price figures are delayed end-of-day values cited to the exchange's published file, never live quotes.